Soluble HLA-G levels in heart transplant recipients: Dynamics and correlation with clinical outcomes

Transpl Immunol. 2023 Feb:76:101771. doi: 10.1016/j.trim.2022.101771. Epub 2022 Dec 5.

Abstract

Purpose: To describe the evolution of the serum levels of soluble HLA-G (s-HLA-G) during the first 12 months after heart transplantation (HT) and to correlate it with clinical outcomes.

Methods: Observational study based in a single-center cohort of 59 patients who underwent HT between December-2003 and March-2010. Soluble HLA-G levels were measured from serum samples extracted before HT, and 1, 3, 6 and 12 months after HT. The cumulative burden of s-HLA-G expression during the first post-transplant year was assessed by means of the area under the curve (AUC) of s-HLA-G levels over time and correlated with the acute rejection burden -as assessed by a rejection score-, the presence of coronary allograft vasculopathy (CAV) grade ≥ 1 and infections during the first post-transplant year; as well as with long-term patient and graft survival. Mean follow-up was 12.4 years.

Results: Soluble HLA-G levels decreased over the first post-transplant year (p = 0.020). The AUC of s-HLA-G levels during the first post-transplant year was higher among patients with infections vs. those without infections (p = 0.006). No association was found between the AUC of s-HLA-G levels and the burden of acute rejection or the development of CAV. Overall long-term survival, long-term survival free of late graft failure and cancer-free survival were not significantly different in patients with an AUC of s-HLA-G levels higher or lower than the median of the study population.

Conclusions: Soluble HLA-G levels decreased over the first year after HT. Higher HLA-G expression was associated with a higher frequency of infections, but not with the burden of acute rejection or the development of CAV, neither with long-term patient or graft survival.

Keywords: Heart transplantation; Soluble HLA-G.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Graft Rejection / metabolism
  • Graft Survival / physiology
  • HLA-G Antigens* / blood
  • HLA-G Antigens* / chemistry
  • Heart Transplantation / adverse effects
  • Humans
  • Patient Outcome Assessment*
  • Transplant Recipients*

Substances

  • HLA-G Antigens